Researchers we empower:

Become Empowered

Biotech & Pharma

Academic Research

Developing the Future of Preclinical Research

We envision a world where animal experiments are obsolete. To make this a reality we are starting with eliminating renal toxicity for compounds entering clinical stages of drug development. This ambition is driven by our human renal ciPTEC cell lines and its use within our growing global network of research professionals. We believe that researchers deserve the best tools available in order to deliver their best work.

Realize Impactful Kidney Research

Build upon extensive
validated research

Our cell models are validated during extensive partnerships with universities and the pharmaceutical industry.

Gather detail on renal
toxicity mechanisms

ciPTEC is a human renal cell line that mimics the proximal tubule cells of the kidney accurately.

Reduce drug
development losses

Cell4Pharma’s ciPTEC technology can predict renal adverse effects in early stages of drug development.

ciPTEC Cell Lines

Cell4Pharma tackles your ADME-tox issues based upon our ciPTEC platforms:
human renal proximal tubule epithelial cell lines stably expressing relevant renal drug transporters.

Stable human
renal cell line

Introducing temperature sensitive genes into a human renal proximal tubule cell allowed us to develop ciPTEC: a human renal cell line with unlimited proliferation capacity at 33°C and highly resemblance with the human kidney at 37°C.

Functional expression of
Relevant Renal Drug Transporters

Just as in the in vivo situation, Cell4Pharma’s ciPTEC is able to transport a wide range of compounds, including organic anions and organic cations. This characteristic is required in order to predict drug-induced kidney injury during drug development and is facilitated by the expression of relevant drug transporters.

Highly Predictive on
DDI and 
Renal Tox

The expression of relevant drug transporters leads to active transport of compounds passing the cell membrane. Using fluorescent markers, drug-drug-interaction studies were developed in collaboration with the pharmaceutical industry. Moreover, the exposure to known toxicants in validation studies resulted in the detection of a range of biomarkers for renal toxicity.

Highly Sensitive
and Specific

Using a multi-parametric high content screening assay developed in collaboration with Astrazeneca we could demonstrate that ciPTEC-OAT1 was highly sensitive and specific using a set of 62 compounds.










Schedule a call with our
team of experts

A member of our team will be in touch asap.